Dark Forest Capital Management LP Buys 78,078 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Dark Forest Capital Management LP grew its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 82.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 172,623 shares of the biotechnology company's stock after buying an additional 78,078 shares during the period. Arrowhead Pharmaceuticals accounts for approximately 0.5% of Dark Forest Capital Management LP's portfolio, making the stock its 22nd largest holding. Dark Forest Capital Management LP owned approximately 0.14% of Arrowhead Pharmaceuticals worth $3,245,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. R Squared Ltd purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter worth approximately $38,000. Van ECK Associates Corp lifted its holdings in shares of Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 1,250 shares during the last quarter. KBC Group NV grew its position in Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after acquiring an additional 1,644 shares in the last quarter. Envestnet Portfolio Solutions Inc. purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at about $190,000. Finally, First Citizens Bank & Trust Co. bought a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $205,000. Hedge funds and other institutional investors own 62.61% of the company's stock.

Insider Activity at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 51,425 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75. Following the sale, the chief executive officer now owns 4,062,377 shares of the company's stock, valued at $61,220,021.39. The trade was a 1.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 275,880 shares of company stock worth $4,034,037 over the last ninety days. 4.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ARWR has been the topic of a number of research reports. Chardan Capital reissued a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. B. Riley restated a "buy" rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $41.44.

Arrowhead Pharmaceuticals Trading Up 2.1 %

NASDAQ:ARWR traded up $0.28 during trading hours on Monday, hitting $13.53. The company had a trading volume of 365,482 shares, compared to its average volume of 1,442,673. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The stock has a 50-day moving average price of $14.57 and a 200 day moving average price of $18.41. The company has a market capitalization of $1.86 billion, a PE ratio of -2.60 and a beta of 0.99. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). On average, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.